Navigation Links
New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
Date:3/31/2008

logical translational and biomedical research and a distinguished fellow of cardiovascular science at CV Therapeutics.

In November 2007, the Company announced that the U.S. Food and Drug Administration was reviewing potential claims to promote Ranexa for HbA1c reduction in coronary artery disease patients with diabetes.

Ranexa is currently indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies. Regadenoson has not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, includi
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... VIENNA , March 5, 2015 ... announce the new generation of OASIS *    ... with enhanced processing power will set a benchmark for ... overcome obstacles and prevent delays whilst optimizing workflow management ... quality, patient comfort and safety for imaging in Neurology, ...
(Date:3/5/2015)... MENLO PARK, Calif. , March 5, 2015 /PRNewswire/ ... company in the emerging field of regenerative medicine, announced ... one of the nation,s top rehabilitation hospitals for spinal ... the Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor ... complete cervical spinal cord injury (SCI). ...
(Date:3/5/2015)... Denmark , March 5, 2015 ... that applies its innovative TransCon technology to address ... present two posters at the ENDO 2015 conference ... The posters will be presented on Thursday, March ... is being held from 1:00pm-3:00pm PST, and are ...
Breaking Medicine Technology:Hitachi Medical Systems Europe Launches the New Generation of OASIS*- The World's Most Powerful Open High-Field 1.2T MRI - A New Level in Patient-Centric Care 2Hitachi Medical Systems Europe Launches the New Generation of OASIS*- The World's Most Powerful Open High-Field 1.2T MRI - A New Level in Patient-Centric Care 3Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 4Ascendis Pharma to Present at ENDO 2015 2
... ORANGE, Calif., Feb. 23, 2011 ... $4.6 billion not-for-profit Catholic healthcare system based in Orange, CA ... West Texas and Eastern New Mexico, has selected Care Management™ ... MDRX ) to streamline patient movement through their 14 hospitals ...
... 23, 2011 Healthpoint today announced the launch of ... Healthpoint Biotherapeutics, along with an updated brandmark and corporate ... identity is designed to communicate the company,s commitment to ... ultimately contribute to improved outcomes and quality of life ...
Cached Medicine Technology:St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 2St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 3St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 4St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 5Healthpoint Launches New Corporate Identity 2Healthpoint Launches New Corporate Identity 3
(Date:3/5/2015)... The global digital PCR (dPCR) and qPCR market is expected ... 2014 to 2019. , The global digital PCR (dPCR) and qPCR ... 2014 to 2019. Although the mature markets such as the U.S., ... (dPCR) and qPCR market the Asia-Pacific region is expected to grow ... growth of the digital PCR (dPCR) and qPCR market is driven ...
(Date:3/5/2015)... FL (PRWEB) March 05, 2015 ... company focused on the peripheral nerve repair market, reported ... ended December 31, 2014 compared to $2.98 million in ... of its growth strategies. , “Our strong fourth ... our peripheral nerve repair products which is driving increased ...
(Date:3/5/2015)... Rhode Island Medical Imaging (RIMI) was pleased to donate ... the Providence College (PC) women’s basketball program’s fight to end ... ‘Think Pink’ uniforms, which were worn during the February 22nd ... at Alumni Hall/Mullaney Gymnasium in Providence, R.I. , ... women’s basketball’s ‘Pink Out’ event,” said Dr. Scott Levine of ...
(Date:3/5/2015)... SuperCloset has released a new video series called ... teach viewers everything they need to know about how to ... takes you from seed all the way through harvest, and ... to prune Grow Like a SuperPro will help take the ... for download for a special introductory price of $19.95. Or ...
(Date:3/5/2015)... March 05, 2015 HMP ... healthcare communications and education, announced today its acquisition ... the nation’s only medical conference designed for health ... and lower limb amputation due to vascular disorders. ... of innovative, evidence-based publications and CME activities across ...
Breaking Medicine News(10 mins):Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 3
... still may benefit from HPV vaccine, study finds , TUESDAY, ... works for women aged 24 to 45 who aren,t already ... cervical cancer and other cervical diseases. , That,s the finding ... in Bogota, Columbia, who noted that women,s rising age at ...
... that a deficiency in a key tumor suppressor gene in the ... The study, conducted in mice that mimic human cancer, points the ... for the disease early. Appearing June 2 in Cancer ... first time that:, Glioblastoma, the type of cancer that afflicts ...
... Minn. -- Mayo Clinic researchers have demonstrated that a noninvasive ... the common cancers above the colon -- including pancreas, stomach, ... 100 Mayo Clinic studies being presented at Digestive Disease Week ... Gastrointestinal (GI) cancers account for approximately one in four cancer ...
... 2009 A closer look at regulatory and clinical ... required, according to an educational advisory by the International ... July 2009 issue of The Journal of Heart ... Elsevier. Thoracic ...
... syndrome results from prolonged flexing of the elbow, experts say ... Nintendo thumb. Then, Guitar Hero wrist. Now, for the latest ... Medically known as cubital tunnel syndrome, cell phone elbow is ... by compression of the ulnar nerve, which passes along the ...
... to use a new, cutting edge diagnostic technology ... , , WOBURN, Mass., and VEDBAEK, Denmark, June ... Center in Savannah, Georgia has implemented AdvanDx,s PNA FISH(R) tests ... conventional methods to help their physicians, pharmacists and nurses improve ...
Cached Medicine News:Health News:Cervical Cancer Vaccine Not Just for Teens 2Health News:Most common brain cancer may start in neural stem cells 2Health News:Most common brain cancer may start in neural stem cells 3Health News:Most common brain cancer may start in neural stem cells 4Health News:Improved DNA stool test could detect digestive cancers in multiple organs 2Health News:Improved DNA stool test could detect digestive cancers in multiple organs 3Health News:More stringent evaluation on the use of generic medications in thoracic transplantation 2Health News:'Cell Phone Elbow' -- A New Ill for the Wired Age 2Health News:'Cell Phone Elbow' -- A New Ill for the Wired Age 3Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 3
... Prefab Orthosis For quick, efficient immobilization ... shell immobilizes and protects the fracture ... adds comfort, support, and conformity to ... the shell may be gently heated ...
Finger /Thumb Splint has a stay that may be shaped to hold finger or thumb in exact degree of flexion. It also has a contact closure....
Combination Oppenheimer with Knuckle Bender - to dorsiflex wrist and flex MCP joints; includes two attachments to extend/flex distal finger joints....
Bunell Mini-Modified Safety Finger Pin reduces PIP flexion contractures....
Medicine Products: